Evidence map›Paper›PMID 28569787›Full record

ArticleCell death & disease2017

Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression.

Shin Kasai, Yoshiyuki Furuichi, Norie Ando, Keiko Kagami, Masako Abe, Takaya Nakane, Kumiko Goi, Takeshi Inukai, Sei Saitoh, Shinichi Ohno and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Shin KasaiDepartments of Pediatrics, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Yoshiyuki FuruichiDepartments of Pediatrics, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Norie AndoDepartments of Pediatrics, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Keiko KagamiDepartments of Pediatrics, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Masako AbeDepartments of Pediatrics, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Takaya NakaneDepartments of Pediatrics, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Kumiko GoiDepartments of Pediatrics, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Takeshi InukaiDepartments of Pediatrics, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Sei SaitohDepartments of Anatomy and Molecular Histology, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Shinichi OhnoDepartments of Anatomy and Molecular Histology, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Shogo OkazakiDivision of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan.
Osamu NaganoDivision of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan.
Hideyuki SayaDivision of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan.ORCID 0000-0001-6610-1902
Kanji SugitaDepartments of Pediatrics, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
University of Yamanashi · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) with mixed lineage leukemia (MLL) gene rearrangements (MLL+ALL) has a dismal prognosis and is characterized by high surface CD44 expression. Known that CD44 has the specific binding sites for a natural ligand hyaluronan (HA), we investigated biological effects of HA with different molecular sizes on MLL+ALL cell lines, and found that the addition of ultra-low-molecular-weight (ULMW)-HA strongly suppressed their thymidine uptakes. The MLL+ALL cell line lacking surface CD44 expression established by genome editing showed no suppression of thymidine uptake. Surface CD44-high B-precursor ALL cell lines other than MLL+, but not T-ALL cell lines, were also suppressed in their thymidine uptakes. The inhibition of thymidine uptakes was because of induction of cell death, but dead cells lacked features of apoptosis on cytospin smears and flow cytometric analysis. The cell death was neither blocked by pan-caspase inhibitor nor autophagy inhibitor, but was completely blocked by necrosis inhibitor necrostatin-1. Necrotic cell death was further supported by a marked release of a high-mobility protein group B1 and morphological changes on transmission electron microscopy. Elevation of intracellular reactive oxygen species production suggested a role for inducing this necrotic cell death. ULMW-HA-triggered cell death was similarly demonstrated in surface CD44-high primary B-precursor leukemia cells. Assuming that ULMW-HA is abundantly secreted at the site of infection and inflammation, this study sheds light on understanding the mechanism of a transient inflammation-associated remission of leukemia. Further, the CD44-targeting may become an effective approach in future for the treatment of refractory B-precursor ALL by its capability of predominantly eradicating CD44-high leukemia-initiating cells.

Indexed as

Biological TransportCell Line, TumorCell SurvivalChildChild, PreschoolFemaleGene ExpressionHMGB1 ProteinHumansHyaluronan ReceptorsHyaluronic AcidImidazolesIndolesInfantMaleMolecular WeightCD44 protein, humanHMGB1 ProteinHMGB1 protein, humanHyaluronan ReceptorsHyaluronic AcidImidazolesIndolesnecrostatin-1Reactive Oxygen SpeciesThymidine

Identifiers

PMID28569787
PMCPMC5520907
OpenAlexW2620859188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.